Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Zurich
Patients with pulmonary hypertension or with interstitial lung disease living below 800 m will be invited to participate in a randomized, cross-over field trial evaluating the hypotheses that: a), exercise capacity during a 2 day sojourn at moderate altitude is reduced in comparison to low altitude; b), exercise capacity during a 2 day sojourn at moderate altitude is improved by nocturnal oxygen therapy compared to room air (sham oxygen) administered during nights at altitude. Outcomes will be assessed at low altitude (Zurich, 490 m, baseline), and during 2 study periods of 2 days each spent at moderate altitude (St. Moritz Salastrains, 2048 m), separated by a wash-out period of at least 2 weeks spent at low altitude (\<800 m). The order of stays at the different altitudes and of the treatments will be randomized.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Precapillary pulmonary hypertension, or interstitial lung disease.
New York Heart Association class 2-3.
Residence at low altitude (\<800m).
You may not be if
Unstable or exacerbated condition
Very severe pulmonary hypertension or interstitial lung disease, New York Heart Association class 4
Requirement for oxygen therapy at low altitude residence
Hypoventilation
More than mild or unstable cardiovascular disease
Use of drugs that affect respiratory center drive
Internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day), inability to perform 6 min walk test.
Previous intolerance to moderate altitude (\<2600m).
Exposure to altitudes \>1500m for \>2 days within the last 4 weeks before the study.